{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:38:04Z","timestamp":1758634684378},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00105-017-4119-9","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T08:23:02Z","timestamp":1517473382000},"page":"298-305","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Arzneimittelassoziierte Angio\u00f6deme","Drug-induced angioedema"],"prefix":"10.1007","volume":"69","author":[{"given":"B.","family":"Sachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"N\u00f6then","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"4119_CR1","series-title":"Bulletin zur Arzneimittelsicherheit 2","volume-title":"Arzneimittel-assoziierte Angio\u00f6deme: Bradykinin im Fokus","author":"BMT Sachs","year":"2017","unstructured":"Sachs B, Meier T (2017) Arzneimittel-assoziierte Angio\u00f6deme: Bradykinin im Fokus. Bulletin zur Arzneimittelsicherheit 2, S 13-22"},{"key":"4119_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.anai.2012.10.008","volume":"109","author":"DM Lang","year":"2012","unstructured":"Lang DM, Aberer W, Bernstein JA et\u00a0al (2012) International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 109:395\u2013402","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4119_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s15007-012-0046-3","volume":"21","author":"K Bork","year":"2012","unstructured":"Bork K (2012) Heredit\u00e4res Angio\u00f6dem durch C1-Inhibitor-Mangel. Allergo\u00a0J 21:109","journal-title":"Allergo J"},{"key":"4119_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/14740338.5.5.643","volume":"5","author":"L Beltrami","year":"2006","unstructured":"Beltrami L, Zingale LC, Carugo S et al (2006) Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 5:643\u2013649","journal-title":"Expert Opin Drug Saf"},{"key":"4119_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/all.12380","volume":"69","author":"M Cicardi","year":"2014","unstructured":"Cicardi M, Aberer W, Banerji A et\u00a0al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602\u2013616","journal-title":"Allergy"},{"key":"4119_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00105-005-1046-y","volume":"57","author":"M-C Hellebrand","year":"2006","unstructured":"Hellebrand M\u2011C, Kojda G, Hoffmann TK, Bas M (2006) Angio\u00f6deme durch ACE-Hemmer und AT1-Rezeptorblocker. Hautarzt 57:808\u2013810. https:\/\/doi.org\/10.1007\/s00105-005-1046-y","journal-title":"Hautarzt"},{"key":"4119_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s40629-014-0009-1","volume":"23","author":"JBK Ring","year":"2014","unstructured":"Ring JBK, Biedermann T et\u00a0al (2014) Leitlinie zu Akuttherapie und Management der Anaphylaxie. Allergo J Int 23:96\u2013112","journal-title":"Allergo J Int"},{"key":"4119_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","volume":"113","author":"SGO Johansson","year":"2004","unstructured":"Johansson SGO, Bieber T, Dahl R et\u00a0al (2004) Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J\u00a0Allergy Clin Immunol 113:832\u2013836","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"4119_CR9","first-page":"138","volume":"12","author":"B W\u00fcthrich","year":"2012","unstructured":"W\u00fcthrich B (2012) Angio\u00f6deme; selten allergisch bedingt. Schweiz Med Forum 12(7):138\u2013143","journal-title":"Schweiz. Med. Forum"},{"key":"4119_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-014-0060-y","volume":"10","author":"J Levy","year":"2014","unstructured":"Levy J, Rivard GE, Wagner E et\u00a0al (2014) Examination of genetic variants involved in generation and biodisposition of kinins in patients with angioedema. Allergy Asthma Clin Immunol 10:60","journal-title":"Allergy Asthma Clin Immunol"},{"key":"4119_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","volume":"128","author":"S Bezalel","year":"2015","unstructured":"Bezalel S, Mahlab-Guri K, Asher I et al (2015) Angiotensin-converting enzyme inhibitor-induced angioedema. Am J Med 128:120\u2013125","journal-title":"Am J Med"},{"key":"4119_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"T Zuberbier","year":"2014","unstructured":"Zuberbier T, Aberer W, Asero R et\u00a0al (2014) The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69:868\u2013887","journal-title":"Allergy"},{"key":"4119_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000368404","volume":"165","author":"TJ Craig","year":"2014","unstructured":"Craig TJ, Bernstein JA, Farkas H et al (2014) Diagnosis and treatment of Bradykinin-mediated Angioedema: outcomes from an Angioedema expert consensus meeting. Int Arch Allergy Immunol 165:119\u2013127","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 1","key":"4119_CR14","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1710-1492-7-S1-S9","volume":"7","author":"A Kanani","year":"2011","unstructured":"Kanani A, Schellenberg R, Warrington R (2011) Urticaria and angioedema. Allergy Asthma Clin Immunol 7(Suppl 1):S9","journal-title":"Allergy Asthma Clin Immunol"},{"key":"4119_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2146\/ajhp150482","volume":"73","author":"M Scalese","year":"2016","unstructured":"Scalese M, Reinaker Ts (2016) Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. Am J Health Syst Pharm 73:873","journal-title":"Am J Health Syst Pharm"},{"key":"4119_CR16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1684\/ejd.2014.2276","volume":"24","author":"L Bouillet","year":"2014","unstructured":"Bouillet L, Boccon-Gibod I, Berard F et al (2014) Recurrent angioedema: diagnosis strategy and biological aspects. Eur J Dermatol 24:293\u2013296","journal-title":"Eur J Dermatol"},{"key":"4119_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10875-015-0228-3","volume":"36","author":"C Faisant","year":"2016","unstructured":"Faisant C, Armengol G, Bouillet L et\u00a0al (2016) Angioedema triggered by medication blocking the Renin\/Angiotensin system: retrospective study using the French National Pharmacovigilance Database. J\u00a0Clin Immunol 36:95\u2013102","journal-title":"J Clin Immunol"},{"key":"4119_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/509899","volume":"79","author":"S Cichon","year":"2006","unstructured":"Cichon S, Martin L, c HH et\u00a0al (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098\u20131104","journal-title":"Am J Hum Genet"},{"key":"4119_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","volume":"343","author":"G Dewald","year":"2006","unstructured":"Dewald G, Bork K (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343:1286\u20131289","journal-title":"Biochem Biophys Res Commun"},{"key":"4119_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/ejhg.2017.104","volume":"25","author":"C Stieber","year":"2017","unstructured":"Stieber C, Cichon S, Magerl M et\u00a0al (2017) Clinical utility gene card for hereditary angioedema with normal C1 inhibitor (HAenC1). Eur J Hum Genet 25:e1\u2013e4. https:\/\/doi.org\/10.1038\/ejhg.2017.104","journal-title":"Eur J Hum Genet"},{"key":"4119_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.iac.2016.08.011","volume":"37","author":"M Bas","year":"2017","unstructured":"Bas M (2017) The angiotensin-converting-enzyme-induced angioedema. Immunol Allergy Clin North Am 37:183\u2013200","journal-title":"Immunol Allergy Clin North Am"},{"key":"4119_CR22","first-page":"408","volume":"107","author":"K Bork","year":"2010","unstructured":"Bork K (2010) Rezidivierende Angio\u00f6deme mit potenzieller Erstickungsgefahr. Dtsch Arztebl Int 107:408","journal-title":"Dtsch Arztebl Int"},{"key":"4119_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2222.2009.03323.x","volume":"40","author":"T Hoover","year":"2010","unstructured":"Hoover T, Lippmann M, Grouzmann E et al (2010) Angiotensin converting enzyme inhibitor induced angio-oedema: a\u00a0review of the pathophysiology and risk factors. Clin Exp Allergy 40:50\u201361","journal-title":"Clin Exp Allergy"},{"key":"4119_CR24","first-page":"1422","volume":"1","author":"AP Kaplan","year":"2011","unstructured":"Kaplan AP (2011) Drug-induced angioedema. J Angioedema 1:1422","journal-title":"J. Angioedema"},{"key":"4119_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","volume":"51","author":"JB Byrd","year":"2008","unstructured":"Byrd JB, Touzin K, Sile S et al (2008) Dipeptidyl peptidase IV in Angiotensin-converting enzyme inhibitor \u2013 associated angioedema. Hypertension 51:141\u2013147","journal-title":"Hypertension"},{"key":"4119_CR26","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1440-1681.2001.03564.x","volume":"28","author":"DJ Campbell","year":"2001","unstructured":"Campbell DJ (2001) The Kallikrein \u2013 Kinin system in humans. Clin Exp Pharmacol Physiol 28:1060\u20131065","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4119_CR27","doi-asserted-by":"publisher","DOI":"10.2174\/1573399813666170214113856","author":"SI Scott","year":"2017","unstructured":"Scott SI, Andersen MF, Aagaard L et al (2017) Dipeptidyl peptidase-4 inhibitor induced angioedema \u2013 an overlooked and potentially lethal adverse drug reaction? Curr Diabetes Rev. https:\/\/doi.org\/10.2174\/1573399813666170214113856","journal-title":"Curr Diabetes Rev"},{"key":"4119_CR28","first-page":"306","volume":"6","author":"M Jean","year":"2015","unstructured":"Jean M, Gera L, Charest-Morin X et al (2015) In vivo effects of Bradykinin B(2) receptor agonists with varying susceptibility to Peptidases. Front Pharmacol 6:306","journal-title":"Front Pharmacol"},{"key":"4119_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/humu.21579","volume":"32","author":"CAL Corte La","year":"2011","unstructured":"La Corte CAL, Carter AM, Rice GI et al (2011) A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 32:1326\u20131331","journal-title":"Hum Mutat"},{"key":"4119_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/hy0202.103054","volume":"39","author":"J Lefebvre","year":"2002","unstructured":"Lefebvre J, Murphey LJ, Hartert TV et al (2002) Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39:460\u2013464","journal-title":"Hypertension"},{"key":"4119_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1086\/496899","volume":"77","author":"QL Duan","year":"2005","unstructured":"Duan QL, Nikpoor B, Dube MP et al (2005) A variant in XPNPEP2 is associated with angioedema induced by angiotensin I\u2011converting enzyme inhibitors. Am J Hum Genet 77:617\u2013626","journal-title":"Am J Hum Genet"},{"key":"4119_CR32","doi-asserted-by":"publisher","first-page":"H1069","DOI":"10.1152\/ajpheart.2000.278.4.H1069","volume":"278","author":"A Kuoppala","year":"2000","unstructured":"Kuoppala A, Lindstedt KA, Saarinen J et al (2000) Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 278:H1069\u2013H1074","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"4119_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaip.2013.07.005","volume":"1","author":"M Baram","year":"2013","unstructured":"Baram M, Kommuri A, Sellers SA et al (2013) ACE inhibitor-induced angioedema. J\u00a0Allergy Clin Immunol Pract 1:442\u2013445","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4119_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","volume":"54","author":"NJ Brown","year":"2009","unstructured":"Brown NJ, Byiers S, Carr D et al (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54:516\u2013523","journal-title":"Hypertension"},{"key":"4119_CR35","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","volume":"73","author":"A Mashaghi","year":"2016","unstructured":"Mashaghi A, Marmalidou A, Tehrani M et\u00a0al (2016) Neuropeptide substance P and the immune response. Cell Mol Life Sci 73:4249\u20134264","journal-title":"Cell Mol Life Sci"},{"key":"4119_CR36","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","volume":"51","author":"DR Miller","year":"2008","unstructured":"Miller DR, Oliveria SA, Berlowitz DR et al (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624\u20131630","journal-title":"Hypertension"},{"key":"4119_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/ACI.0b013e328362b835","volume":"13","author":"PF Campo","year":"2013","unstructured":"Campo PF, Tah\u00eda D, Canto G, Mayorga C (2013) Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol 13:337","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4119_CR38","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","volume":"172","author":"S Toh","year":"2012","unstructured":"Toh S, Reichman ME, Houstoun M et al (2012) Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 172:1582\u20131589","journal-title":"Arch Intern Med"},{"key":"4119_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","volume":"26","author":"JB Byrd","year":"2006","unstructured":"Byrd JB, Adam A, Brown NJ (2006) Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26:725\u2013737","journal-title":"Immunol Allergy Clin North Am"},{"key":"4119_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2500\/ajra.2014.28.3989","volume":"28","author":"ST C-CR","year":"2014","unstructured":"Stauber T C-CR, Goldberg A (2014) Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors. Am J Rhinol Allergy 28:54","journal-title":"Am J Rhinol Allergy"},{"key":"4119_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","volume":"356","author":"FH Messerli","year":"2000","unstructured":"Messerli FH, Nussberger J (2000) Vasopeptidase inhibition and angio-oedema. Lancet 356:608\u2013609","journal-title":"Lancet"},{"key":"4119_CR42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/all.12680","volume":"70","author":"M Bas","year":"2015","unstructured":"Bas M, Greve J, Strassen U et\u00a0al (2015) Angioedema induced by cardiovascular drugs: new players join old friends. Allergy 70:1196\u20131200","journal-title":"Allergy"},{"key":"4119_CR43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C et al (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693\u20131697","journal-title":"Lancet"},{"key":"4119_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0162-3109(99)00133-2","volume":"43","author":"C Blais Jr.","year":"1999","unstructured":"Blais C Jr., Rouleau JL, Brown NJ et al (1999) Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 43:293\u2013302","journal-title":"Immunopharmacology"},{"key":"4119_CR45","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","volume":"359","author":"A Adam","year":"2002","unstructured":"Adam A, Cugno M, Molinaro G et al (2002) Aminopeptidase P in individuals with a\u00a0history of angio-oedema on ACE inhibitors. Lancet 359:2088\u20132089","journal-title":"Lancet"},{"key":"4119_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.102.038067","volume":"303","author":"G Molinaro","year":"2002","unstructured":"Molinaro G, Cugno M, Perez M et al (2002) Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a\u00a0slower degradation of des-arginine9-Bradykinin. J\u00a0Pharmacol Exp Ther 303:232\u2013237","journal-title":"J Pharmacol Exp Ther"},{"key":"4119_CR47","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","volume":"23","author":"G Pare","year":"2013","unstructured":"Pare G, Kubo M, Byrd JB et al (2013) Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 23:470\u2013478","journal-title":"Pharmacogenet Genomics"},{"key":"4119_CR48","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","volume":"20","author":"AV Woodard-Grice","year":"2010","unstructured":"Woodard-Grice AV, Lucisano AC, Byrd JB et al (2010) Sex-dependent and race-dependent association of XPNPEP2 C\u20112399\u202fA polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 20:532\u2013536","journal-title":"Pharmacogenet Genomics"},{"key":"4119_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","volume":"60","author":"NJ Brown","year":"1996","unstructured":"Brown NJ, Ray WA, Snowden M et al (1996) Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60:8\u201313","journal-title":"Clin Pharmacol Ther"},{"key":"4119_CR50","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","volume":"165","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Kim HJ, Rusnak J et\u00a0al (2005) Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165:1637\u20131642","journal-title":"Arch Intern Med"},{"key":"4119_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/01.HYP.33.1.323","volume":"33","author":"PE Gallagher","year":"1999","unstructured":"Gallagher PE, Li P, Lenhart JR et al (1999) Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33:323\u2013328","journal-title":"Hypertension"},{"key":"4119_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","volume":"10","author":"T Morimoto","year":"2004","unstructured":"Morimoto T, Gandhi TK, Fiskio JM et al (2004) An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J\u00a0Eval Clin Pract 10:499\u2013509","journal-title":"J Eval Clin Pract"},{"key":"4119_CR53","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/01.HYP.0000064942.77814.26","volume":"41","author":"B Hornig","year":"2003","unstructured":"Hornig B, Kohler C, Schlink D et al (2003) AT1-receptor antagonism improves endothelial function in coronary artery disease by a\u00a0bradykinin\/B2-receptor-dependent mechanism. Hypertension 41:1092\u20131095","journal-title":"Hypertension"},{"key":"4119_CR54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","volume":"111","author":"DJ Campbell","year":"2005","unstructured":"Campbell DJ, Krum H, Esler MD (2005) Losartan increases bradykinin levels in hypertensive humans. Circulation 111:315\u2013320","journal-title":"Circulation"},{"key":"4119_CR55","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1345\/aph.1P630","volume":"45","author":"CJ Beavers","year":"2011","unstructured":"Beavers CJ, Dunn SP, Macaulay TE (2011) The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother 45:520\u2013524","journal-title":"Ann Pharmacother"},{"key":"4119_CR56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1081-1206(10)60288-8","volume":"101","author":"BR Haymore","year":"2008","unstructured":"Haymore BR, Yoon J, Mikita CP et al (2008) Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a\u00a0meta-analysis. Ann Allergy Asthma Immunol 101:495\u2013499","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4119_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1755-5922.12053","volume":"32","author":"JR Dalzell","year":"2014","unstructured":"Dalzell JR, Seed A, Berry C et\u00a0al (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther 32:13\u201318","journal-title":"Cardiovasc Ther"},{"key":"4119_CR58","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1124\/jpet.103.064105","volume":"309","author":"AC Sulpizio","year":"2004","unstructured":"Sulpizio AC, Pullen MA, Edwards RM et al (2004) The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J\u00a0Pharmacol Exp Ther 309:1141\u20131147","journal-title":"J Pharmacol Exp Ther"},{"key":"4119_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jnnp-2014-308097","volume":"86","author":"R Hurford","year":"2015","unstructured":"Hurford R, Rezvani S, Kreimei M et al (2015) Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatr 86:520\u2013523","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"4119_CR60","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1212\/01.WNL.0000058840.66596.1A","volume":"60","author":"MD Hill","year":"2003","unstructured":"Hill MD, Lye T, Moss H et al (2003) Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 60:1525\u20131527","journal-title":"Neurology"},{"key":"4119_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir AM, Durinx C, Scharpe S et al (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209\u2013294","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4119_CR62","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696\u20131705","journal-title":"Lancet"},{"key":"4119_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","volume":"2","author":"F Remm","year":"2016","unstructured":"Remm F, Franz WM, Brenner C (2016) Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease. Eur Heart J Cardiovasc Pharmacother 2:185\u2013193","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"4119_CR64","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/ajt.13151","volume":"15","author":"D Fantus","year":"2015","unstructured":"Fantus D, Thomson AW (2015) Evolving perspectives of mTOR complexes in immunity and transplantation. Am J Transplant 15:891\u2013902","journal-title":"Am J Transplant"},{"key":"4119_CR65","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.07371009","volume":"5","author":"M Duerr","year":"2010","unstructured":"Duerr M, Glander P, Diekmann F et\u00a0al (2010) Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5:703\u2013708","journal-title":"Clin J Am Soc Nephrol"},{"key":"4119_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000099584","volume":"214","author":"E Mahe","year":"2007","unstructured":"Mahe E, Morelon E, Lechaton S et\u00a0al (2007) Angioedema in renal transplant recipients on sirolimus. Dermatology (Basel) 214:205\u2013209","journal-title":"Dermatology (Basel)"},{"key":"4119_CR67","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1398-9995.2010.02398.x","volume":"65","author":"JB Byrd","year":"2010","unstructured":"Byrd JB, Woodard-Grice A, Stone E et al (2010) Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 65:1381\u20131387","journal-title":"Allergy"},{"key":"4119_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-50351-5","volume-title":"Arzneiverordnungs-Report 2016","author":"UPD Schwabe","year":"2016","unstructured":"Schwabe UPD, Ludwig K\u2011D, Klauber J (2016) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-017-4119-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:01:25Z","timestamp":1719784885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-017-4119-9"}},"subtitle":["Bradykinin im Fokus","Focus on bradykinin"],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4119"],"URL":"https:\/\/doi.org\/10.1007\/s00105-017-4119-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"1 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Sachs, T.\u00a0Meier, M.M.\u00a0N\u00f6then und J.\u00a0Stingl geben an, dass kein Interessenkonflikt besteht. C.\u00a0Stieber erhielt von der Firma Shire Reisekostenunterst\u00fctzung und ein Honorar f\u00fcr eine T\u00e4tigkeit in einem Advisory Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}